Introduction
Renal failure poses a grave threat to individual health and a growing burden on American health care. From 2000 to 2013, the prevalence of end-stage renal disease (ESRD) rose by 68%, affecting 0.2% of the population (1) . Renal failure commonly occurs in association with obesity, diabetes, hypertension and vascular disease, and ESRD patients have 3.6-fold higher adjusted mortality than the general population (1) . The survival benefit of renal transplantation has long been established, with mortality rates 48-82% lower in graft recipients than matched controls (2). Transplant's potential is limited by a chronic and worsening shortfall in supply of donor organs, with expansion of the waitlist and corresponding increases in waiting time (3) . Longer wait times lead to greater attrition on the list, with >8000 patients dying or being judged too ill to remain listed in 2014 (4) . The rate at which candidates are delisted for declining medical status is increasing rapidly, from <1000 people in 2007 to nearly 3400 in 2014 (4, 5) . Beyond those delisted, the candidate pool fares more poorly with prolonged dialysis, rendering efforts to maximize utility of the existing organ supply imperative (1, (6) (7) (8) .
The estimated posttransplant survival (EPTS) score, adopted in 2014, was designed to improve the efficacy of kidney transplantation by better matching the highest quality grafts with those candidates with the greatest projected life expectancy, as measured by age, dialysis vintage, diabetes status and prior transplantation (6, 7) . Although EPTS may represent an advance over previous systems, its prognostic value and inherent inequity for elderly and long-duration ESRD patients are areas for improvement (8) . To enhance the predictive value of a survival metric for transplant candidates, better quality health information is necessary. The fundamental limitation of demographic and comorbidity-based assessments is variable expressivity of comorbidity terms (9) . The severity and context of these labels in administrative data sets is typically incomplete. Expansion of the number of variables, as in the Charlson Comorbidity Index, can offset these limitations to a certain point, above which there is little value to more comprehensive enumeration of disease labels (10, 11) . Addition of a biometric element provides a new domain for assessing health. Sarcopenia, or cachectic muscle wasting, has been shown to have a negative impact on renal patients' survival (12) , as have bone density (13) , arterial stiffness (14) and aortic geometry (15) . Although valuable, these tests require biochemical or radiographic studies, with associated cost and logistic considerations limiting their utility as recurring tools for patient assessment. Clinical measures of physiological reserve, or frailty, have also been suggested as a means of identifying high-risk transplant candidates (16) (17) (18) . As with sarcopenic or metabolic parameters, however, frailty assessments require direct candidate interaction, making even intermittent updates logistically complicated. In addition, subjective elements of the frailty score are susceptible to bias, especially when affecting candidacy for a scarce resource (19) . To augment existing risk-stratification and organ-allocation algorithms, other options must be considered for a simple, objective, readily updated criterion of ESRD patient fitness.
We hypothesized that because likelihood of admissions in ESRD is sensitive to comorbidity burden, frailty, sarcopenia, medical adherence and psychosocial considerations, the relative capacity of a patient to avoid hospitalization is itself a measure of fitness. The immediate reasons for inpatient admission are varied, but each represents a summation of comorbidities, physiological reserve and psychosocial considerations. The relative ability of a patient to persist outside the hospital with a given set of comorbidities implies an inherent level of fitness, with frequent or prolonged admissions being suggestive of a frail or decompensated state. Prior research by Grams demonstrated that transplant recipients' burden of readmission tends to mirror their history of admissions in the pretransplant year (20) . We expanded on this finding to establish that ESRD patients with a high burden of hospitalization in the year prior to transplantation have not only increased readmissions but also inferior graft and patient survival following transplantation (21) . The purpose of this study was to ascertain whether earlier assessment of renal transplant candidates' hospitalization patterns could be used to predict waitlist survival, likelihood of receiving a transplant, and posttransplant survival and benefit. A predictive index including these data could be valuable to clinicians and patients for risk assessment and education at the individual level, whereas the potential for improved organ utility could aid development of future longevity-matching algorithms.
Methods

Data sources and study population
Approval for data collection and analysis was obtained through the Emory University institutional review board. United States Renal Data System standard analysis files and hospital data from all adult renal-only transplant recipients among patients with ESRD between January 1, 2000, and December 31, 2010, were examined (N = 207 191). Follow-up data were measured through September 2011. Patients with survival of <1 year following waitlisting were excluded (n = 10 068). Candidates who went on to receive a living donor transplant were also excluded. To capture admissions data, participants were limited to those patients with continuous primary coverage through Medicare for at least 1 year following waitlisting. A total of 51 111 patients met selection criteria for inclusion in the study. Patient demographics and comorbidities were captured when starting dialysis through the Centers for Medicare and Medicaid Services Medical Evidence CMS-2728 form.
Study variables
Outcomes: Outcome measures included time to patient death on the waitlist, hospital admissions over subsequent waitlist years, receipt of a renal allograft, and posttransplant graft and recipient survival. A subset of Figure 1 : Distribution of total days admitted among patients in the first year after waitlisting (excluding those with no admissions, n = 23 983, 47% of total). patients with continuous primary Medicare coverage over the entirety of the study period was used to follow changes in yearly hospitalizations (n = 50 312). Time to death was calculated as the number of days from waitlisting until the date of death. Posttransplant time to death was measured from the date of transplant discharge to death. Time to graft failure was defined as the number of days from date of discharge to graft failure date (return to dialysis) or death. For each analysis, patients were censored at loss to follow-up or date of study end.
Patient characteristics:
The primary predictor of interest was hospitalization in the first 365 days following waitlisting, which was categorized as 0, 1-7, 8-14 and ≥15 days. Hospitalizations were defined by admission and discharge dates. Patient covariates included demographic and clinical characteristics at the time of initiating dialysis, including age, race, sex, etiology of renal failure, comorbid conditions, BMI at time of transplant listing, and history of prior solid organ transplant. Age and dialysis vintage were updated at the time of waitlisting.
Statistical analysis
Survival from time of listing and posttransplant patient and graft survival were examined by Kaplan-Meier methods and the log-rank test. Chisquare statistics and multivariable Cox regression analyses, including some with interaction variables, were used to study relationships between clinical risk predictors and outcome. Multivariable models were defined with an initial group of clinically important variables that met criteria for confounding variables (i.e. association with preadmission, a risk factor for the outcome, and not in the causal pathway between preadmission and outcome). Effect modification was studied using interaction terms between preadmission and EPTS variables in the multivariable model. Proportional hazards assumptions for Cox models were tested using goodness of fit, log-log survival curves and partial likelihood estimation. Piecewise modeling was used in lieu of time-varying covariates after determination of consistency across follow-up intervals. Comparison of C statistics was used to assess relative fidelity of EPTS and waitlist admission models in predicting postlisting survival. SAS version 9.4 (SAS Institute, Cary, NC) was used for all data management and analysis.
Results
Study population
Among 207 191 patients with complete covariate data, 4.9% did not survive at least 365 days after listing. When normalized to their postwaitlist survival, persons who died in the first waitlist year spent 14.9% of their postlisting lifespan hospitalized compared with 2.5% among those in the final study cohort (p = 0.0001). There were 67 988 admissions and 464 597 hospital days in the study (1.33 admissions and 9.08 inpatient days per person per year). The distribution of admissions among the population is shown in Figure 1 , excluding those never admitted (n = 23 983, 47% of population). In total, 95% of patients were admitted for <42 days, and 99% were admitted for <100 days, with the proportions of patients with 1-7, 8-14, or ≥15 hospital days being 23%, 12%, and 18%, respectively. As displayed in Table 1 , candidates did not differ significantly in age across hospitalization cohorts. Female sex and white race were more common among heavily admitted groups. Rise in mean dialysis vintage across successive admission groups was not statistically significant. There was a stepwise trend in prior organ transplant and diabetes as the etiology of ESRD. Finally, major comorbidities such as congestive heart failure, coronary artery disease, peripheral vascular disease and chronic obstructive pulmonary disease (COPD) were all more common among those with higher numbers of days inpatient in the first year on the waitlist. Despite these differences, admission cohorts differed minimally in EPTS score (p < 0.0001).
Survival and progression to transplantation after waitlisting Patients with increased admission requirements during the first waitlist year had inferior survival and substantially lower chance of receiving a renal allograft. The proportion of patients who were transplanted by study end was 44.7% among nonadmitted patients, 38.2% in the group with 1-7 days hospitalized, 31.0% in patients with 8-14 days hospitalized, and 20.3% for those with ≥15 days hospitalized. Death without transplant occurred in 36.8%, 45.2%, 53.8%, and 68.4% of these respective groups. As seen in Figure 2 , when analysis was restricted to patients with continuous primary Medicare coverage over the entire study period (n = 50 312), subsequent waitlist outcome differed greatly between early admission subgroups. The overall hazard ratio for transplant declined with greater early admission from 0.719 for the group with 1-7 days hospitalized, 0.610 for 8-14 days hospitalized, and 0.552 for ≥15 days hospitalized (nonadmitted patients as reference, p < 0.0001 for each comparison between successive cohorts). Nonadmitted patients had a greater chance of transplant than death for each of the next 5 years following the end of the reference year, whereas those in the group with 1-7 hospital days who had been on the waitlist for 3.5 years had a greater chance of dying each subsequent year than they did of receiving an organ. Patients with >1 week admitted had the poorest outlook, with death rates exceeding transplant rates within 2 years after listing. Among patients in the most hospitalized cohort, 46% of those surviving for at least 2 years on the waitlist remained in the highest intensity admission tier for the second year, whereas 20% were not hospitalized at all in the second year. Second-year performance for these subgroups showed a dose-dependent relationship between admission and subsequent events, with a stepwise decrement in likelihood of receiving a transplant (27.6% vs. 13.1%, p < 0.0001 for all comparisons) and 5-year survival from listing (65.4% vs. 38.8%, p < 0.0001 for all comparisons). Those patients remaining on the waitlist without either dying or being transplanted spent proportionately less time in the hospital with each subsequent year.
The results of Kaplan-Meier analysis of survival after waitlisting are depicted in Figure 3 . Later transplantation was associated with markedly better outcome at each level of early waitlist admission. Among those who did not undergo transplant ( Figure 3A) , survival was worse, with successively higher early waitlist hospitalization ranging from 39% at 5 years for nonadmitted patients to 18% for those with >14 days inpatient (p < 0.0001 for comparisons between successive cohorts). This effect was most apparent midway during the follow-up period because survival in all groups was universally poor by 10 years from listing. In those who went on to be transplanted ( Figure 3B ), hospitalization also showed a dosedependent relationship with survival, although effect size was smaller than in nontransplanted counterparts (5-year survival 69-82%, p < 0.0001 between each admission cohort).
Cox multivariable analysis was performed to assess risk factors for candidate death after waitlisting, with results shown in Table 2 . Among demographic attributes, candidate age added a small increase in risk, and female sex was mildly protective. Nonwhite race was strongly associated with decreased risk of death. Etiology of ESRD varied in importance, with diabetes conferring survival risk, and hypertension and glomerular nephritis conferring a moderate benefit. Coexisting medical diseases reported on the CMS-2728 form were each statistically significant, with observed effect strength greatest for COPD. Low BMI at time of listing was associated with inferior survival, whereas obesity had a slight protective effect. Dialysis vintage showed a discrete risk for each additional year's duration of ESRD prior to listing. Prior transplant was protective for survival from listing, and transplant after listing imparted 70% lower risk of death. Compared with conventional risk factors, the number of days spent hospitalized in the first year following listing had a much more powerful impact on survival, with successively greater hazard ratios for each admission cohort. Figures 4(A) and (B) . Despite the elapsed time between waitlisting and transplantation and the potential for secondary selection at time of transplant, a stepwise survival decrement with waitlist hospitalization persisted (p < 0.0001 between successive cohorts for both patient and graft survival). This correlation was furthered studied using Cox multivariable analysis, with results for models of posttransplant death in Table 3 and death or graft loss in Table 4 . As shown, the hazard ratio for the outcome of interest in both models showed statistically and clinically significant dose-dependent increases with increased length of first-year waitlist hospitalization. Among patients who were in the highest admission cohort in the first year and spent at least one more year waitlisted prior to transplant, 3-year survival did not show a statistically significant detriment, with greater burden of admissions in the second waitlist year (78.6% vs. 74.8% for no hospitalizations vs. >2 weeks inpatient in the second year, p = 0.06).
A B
Transplantation and survival after listing
Benefit from renal transplantation was estimated by using Cox multivariable modeling of postlisting survival using interaction variables for various intensities of firstyear waitlist admission and subsequent transplantation. As shown in Table 5 , the hazard ratio for postlisting death rose incrementally with each successive level of admissions, and there was a consistent benefit (or relative reduction in hazard ratio) with transplant for each index level of admission. Among patients with admission for a period greater than the index level in each model, the relative reduction in hazard ratio for death actually increased at higher thresholds for admission. Although these data were statistically significant, Table 5 also showed the relatively small numbers of patients in higher admission cohorts who underwent transplant. Figure 5(A) shows the mean number of first waitlist year inpatient days as a function of EPTS score at the time of waitlisting. Although higher EPTS cohorts trended toward having increased numbers of inpatient days (p < 0.0001 between tertiles of EPTS scores 1-33, 34-66, and 67-99), there was considerable heterogeneity in admission requirements within each EPTS group. Overall survival at 5 years after listing is displayed in Figure 5 (B) as a function of EPTS and first-year waitlist admissions. Across the range of EPTS scores, increased intensity of admissions showed a stepwise decrement in survival. In total, there were 12 004 patients in groups for which listing EPTS score was >20 but that had survival better than that observed in the highest admission low-EPTS subgroups. The potential utility of early waitlist hospitalization as a risk assessment tool for subsequent survival was assessed by comparing parsimonious models of patient survival. The C statistic of a model using only EPTS was 0.69 (95% CI 0.67-0.73), whereas one based on waitlist admissions alone had a C statistic of 0.76 (95% CI 0.74-0.80).
Longevity estimation
Discussion
In this study, we sought to understand the prognostic significance of high baseline hospitalization rates among renal transplant waitlist candidates. We hypothesized that documentation of hospital admissions would identify those candidates at risk of death while awaiting an CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; ESRD, end-stage renal disease; HR, hazard ratio; HTN, hypertension; PVD, peripheral vascular disease.
organ. We found that this was indeed the case, with greatly decreased survival among patients spending >1 week inpatient in the first 12 mo after listing. Those candidates with high early waitlist hospitalizations had persistently high admission requirements over the remainder of their waitlist course and had a substantially A B Figure 4 : Kaplan-Meier analyses of death (A) and composite death and graft loss (B) following renal transplantation. CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; ECD, extended criteria donor; HR, hazard ratio; PVD, peripheral vascular disease. lower chance of later transplantation. Survival was diminished regardless of subsequent transplantation, and although patients in these higher admission cohorts still derived a survival advantage from transplant, organ utility was inferior in these groups. Importantly, these variations in outcome occurred between groups that were minimally different in mean EPTS score and thus would not be expected using existing predictive schemes. Finally, waitlist hospitalization predicted subsequent survival with higher fidelity than EPTS.
We previously showed that hospitalization in the year immediately prior to transplant is a marker of increased readmission and decreased survival postoperatively (21) . In this report, we sought to extend our analysis back to a baseline waitlisting admission requirement as a predictor of subsequent waitlist and transplant outcome. Excess admissions have face validity as a measure of ESRD patient fitness in large part because the renal failure population is marked by a pattern of hospitalization and rehospitalization. ESRD patients experience 1.7 hospitalizations per patient year compared with 0.3 admission in the general population aged >65 years and 1.1 admissions for transplant recipients (1, 22) . This high rate reflects not only comorbidity burden but also chronic fluid and electrolyte management problems (23, 24) . Admissions among ESRD patients portends poor outcome, with threefold higher rates of in-hospital death and 87% higher likelihood of readmission or death within 30 days after discharge (1, 25) . As the severity of the acute episode increases, renal patients suffer disproportionately worse outcomes, as shown by studies of mechanical ventilation, intensive care unit admission and in-hospital cardiopulmonary resuscitation (26) (27) (28) . Hospitalization also incurs a substantial cost, with 40% of Medicare ESRD expenditures going to inpatient care in 2014 (22) .
Although a number of approaches have been suggested for better determining the survival capacity of prospective transplant recipients (12) (13) (14) (15) (16) (17) (18) , records of hospitalization offer elegant insight into fitness and physiological reserve.
Our work suffers from the standard limitations of retrospective analyses of large data sets. The quality and context of comorbidity data are sparse, and associations between risk factors and observed outcomes are inferential. In addition, the construction of our study cohort has the potential to introduce bias both from the requirement for continuous Medicare coverage as a means of gathering billing data and from the requirement for one full year of postlisting survival from which to determine a baseline level of admissions. Furthermore, our analyses cannot account for selection bias in the decision to waitlist or transplant a candidate whose comorbidity burden or pattern of admissions does not fully reflect individual performance or fitness assessments by their provider. Although patients in the most heavily admitted group with high second-year waitlist hospitalizations had roughly similar 3-year survival after transplant, the likelihood of receiving a graft in that group was only 13%, suggesting that a small subgroup of patients either has preserved survival capacity despite persistently high admission requirements or is salvaged through intensive hospitalization. Finally, the circumstances surrounding a given admission cannot be fully defined using our data source, and it should be understood that some admissions are undoubtedly of benefit to the patient, especially for preemptive or elective procedures.
Despite these limitations, we believe this analysis adds significantly to the discussion of risk stratification and candidate assessment in renal transplantation. We Table 5 : Interaction models of first-year waitlist admissions and subsequent transplantation for prediction of death after waitlisting at various admission thresholds selected our cohort from those ESRD patients already listed to avoid capturing hospitalizations inherent to the onset of ESRD or those incidental to the transplant evaluation. Nearly 5% of patients deemed eligible for transplant listing did not survive for the full 12 mo needed for the reference interval in this study. When standardized to postlisting lifespan, these patients spent a significantly greater proportion of their time after listing hospitalized than did those with at least 1-year survival. Among patients in the final cohort, the overall admission rate was 1.3 per person per year, and 30% of patients spent >1 week per year hospitalized. These findings underscore the medical complexity and marginal health of the population awaiting transplantation but will likely come as a surprise to many transplant providers, given the fact that most pretransplant admissions do not occur at the actual transplant center. We found that those patients with initial high resource requirements continued to have excess hospitalizations and were more likely to die than to receive a transplant with each subsequent year following listing. Among those patients in high-admission cohorts who receive a renal allograft, there is still a reduction in the mortality risk after listing associated with transplantation, but posttransplant graft and patient survival is inferior to that of less heavily admitted patients. This reduced survival constitutes diminished graft utility in heavily admitted patients. Discrepancies in survival capacity associated with excess waitlist admissions are not reflected in the EPTS score of the patient, and although our data set predates the new kidney allocation system, the disparity in outcome across admission cohorts would confound modern survival projections. In terms of longevity matching, consideration of baseline admission requirements offers predictive ability at least equivalent to the existing EPTS assessment.
Conclusions
In summary, hospitalization while waitlisted for renal transplantation is a marker of reduced survival on dialysis, decreased likelihood of transplantation and diminished survival with a renal allograft. Admission records are an objective measure that incorporates many domains of candidate fitness, including comorbidity burden, medical compliance and physiological reserve. This information has potential to provide a measure of compensation by which to adjust the liability imparted by classically understood risk factors. These data can be updated continuously from all sources by accessing payer records without dedicated observations or visits to a transplant center. As such, incorporation of baseline admission rate has the potential to add greatly to risk stratification for waitlisting and transplant allocation. This nascent area of study must be pursued in greater depth to validate the predictive ability of admissions patterns with regard to waitlist and posttransplant survival. Additional areas of inquiry must include efforts to define deleterious patterns of admission and to guide proactive efforts to correct elements of patient health to reverse these risks.
